US Capitol Capsule: Regulatory, Legislative, Legal and Political Biopharma News

This past week in US regulatory, legislative, legal and political news affecting the biopharmaceutical industry included the indictment of a former GlaxoSmithKline PLC senior-level manager, who went from being regarded as one of the world's top protein biochemists to a becoming a thief, scheming with one of her coworkers to steal trade secrets from the London-based drug and vaccine maker; the Senate Health panel chairman's decision to take a step-by-step approach for overhauling the US biomedical enterprise, which ignores several measures, like one focused on antibiotics development, that were included in the House 21st Century Cures Act; and threats by House and Senate lawmakers to bring criminal contempt actions against former Turing Pharmaceuticals Inc. CEO Martin Shkreli if he ignores subpoenas to testify and turn over documents about why his firm hiked up the price of a more than 60-year-old drug; plus other Washington news.